SCHEMBL524703

SCHEMBL524703

OC1CCCCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560071 1.00
SCHEMBL14429808 0.92
SCHEMBL246993 0.92
SCHEMBL2407814 0.92
Hydrochloric Acid SCHEMBL28069785 0.89
Methane SCHEMBL28927391 0.89
SCHEMBL17818430 0.87 TSHR (0.41)
SCHEMBL24475242 0.86 TSHR (0.38)
Tetrahydrofuran SCHEMBL6661741 0.86 ALDH1A1 (0.42)
Cyclopentanol SCHEMBL971085 0.82 TSHR (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106397391-A Reduction, alcoholization and splitting method of watermelon ketone 安徽爱有澄生物科技有限公司 2017-02-15 CN claimed
US-8883776-B2 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 US claimed
EP-2222664-B1 CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2014-10-29 EP claimed
EP-2222664-A1 CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2010-09-01 EP claimed
WO-2009067401-A1 CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-28 WO claimed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US claimed
WO-2024218296-A1 COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS H. LUNDBECK A/S (DK) 2024-10-24 WO disclosed
EP-4422750-A1 LRRK2 INHIBITORS H. Lundbeck A/S (DK) 2024-09-04 EP disclosed
US-11993612-B2 LRRK2 inhibitors H. LUNDBECK A/S (DK) 2024-05-28 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-20230416272-A1 LRRK2 INHIBITORS H. LUNDBECK A/S (DK) 2023-12-28 US disclosed
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11780851-B2 LRRK2 inhibitors H. LUNDBECK A/S (DK) 2023-10-10 US disclosed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US disclosed
US-5554794-A REDUCING INTAKE VALVE DEPOSITS IN PORT FUEL INJECTED ENGINES SHELL OIL COMPANY (US) 1996-09-10 US disclosed
US-5403859-A PHENYLENE-CYCLIC ETHER COMPOUNDS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-04-04 US disclosed
EP-0375404-B1 Heterocyclic derivatives ICI PLC (GB) 1994-02-09 EP disclosed
US-5234950-A Antiallergens, antiinflammatory agents; cardiovascular disorders, antiarthritic IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-10 US disclosed
US-5098930-A Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-03-24 US disclosed
EP-0012622-A2 1-Tosloxy-2,2-ethylenedioxy-6,10-dimethyl undecanes and undecenes, process for the preparation of 2S*,3R*-3-benzyloxy-6,6-ethylene dioxy-2-methyl-2-(5'-hydroxy-4'-methylpentyl)-oxepane, and use of the latter for the preparation of oxepan-3-ol derivatives ORTHO PHARMACEUTICAL CORPORATION (US) 1980-06-25 EP disclosed